Exclusive special offer and discount title banner vector image

GLOBAL CELL THERAPY BIOPROCESSING MARKET FORECAST 2024-2032

SCOPE OF THE REPORT

Global Cell Therapy Bioprocessing Market by Technology (Bioreactor, Electrospinning, Genome Editing Technology, Ultrasonic Lysis, Controlflow Centrifugation, Cell Immortalization Technology, Viral Vector Technology, Lyophilization) Market by Indication (Cardiovascular Disease, Oncology, Wound Healing, Orthopedic) Market by Cell Type (Stem Cell, Immune Cell, Pluripotent Stem Cell, Hematopoetic Stem Cell, Human Embryonic Stem Cell) Market by End-user (Hospital and Clinic, Regenerative Medicine Center, Diagonostic Center, Academic and Research Institute) by Geography


MARKET OVERVIEW

The global cell therapy bioprocessing market is forecasted to grow at a CAGR of 13.01% during the forecast period 2024-2032

Cell therapy bioprocessing involves the equipment, technologies, and processes required to manufacture cell-based therapies. It includes steps like cell sourcing, processing, expansion, differentiation, and delivery. The ongoing advancements and regulatory approvals in the field of regenerative therapies fuel the momentum in this market. These therapeutic developments in areas such as cancer, neurological disorders, and cardiovascular diseases are contributing to the growing demand for efficient bioprocessing solutions.

In addition to the essential steps involved in cell therapy bioprocessing, there is a notable emphasis on continuous innovation within the market. Advancements in bioprocess optimization and automation are increasingly vital to facilitate large-scale production efficiently. Bioprocessing instruments, media, reagents, and other tools provided by the cell therapy bioprocessing market contribute to the reliable manufacturing of cell therapies. This focus on optimization and automation is not only aimed at improving the scalability of production but also at addressing challenges related to consistency and cost-effectiveness.

Cell Therapy Bioprocessing Market

Read our latest blog on the Cell Therapy Bioprocessing Market

GROWTH ENABLERS

Key growth enablers of the global cell therapy bioprocessing market:

  • Increased investment and innovation in cell-based regenerative medicine approaches for complex diseases
  • Technology advancements enabling optimization of cell harvesting, expansion, engineering, and delivery steps
    • Advances in bioprocessing technologies are driving optimization across the cell therapy production workflow. This includes improved cell harvesting methods, 3D culture systems for automated cell expansion, genetic engineering tools like CRISPR to edit cells, downstream purification innovations, and novel delivery mechanisms such as cell encapsulation devices. These methods allow more tailored manufacturing of cell therapies with higher cell quality and process yields.
  • Industry and academia partnerships providing end-to-end infrastructure and expertise
  • Supportive regulatory guidelines for accelerated approval pathways of cell therapies
  • Rising cases of cancer, autoimmune disorders, and degenerative conditions globally

GROWTH RESTRAINTS

Key growth restraining factors of the global cell therapy bioprocessing market:

  • High production costs and complexity associated with cell therapy manufacture
  • Limitations in scaling processes from laboratory to clinical setting
    • Scaling up cell therapy manufacturing from laboratory scale to clinical and commercial production continues to pose major challenges that restrain the growth of the bioprocessing market. Small-scale protocols and processes developed in the lab often fail to translate well to larger batch sizes. 
    • There are difficulties maintaining the necessary environmental conditions, raw material consistency, growth kinetics, and process control needed for reproducible production at scale. For instance, scaled-up cultures can negatively impact cell purity, potency, and quality due to shear stress and less uniform exposure. 
    • Additionally, optimizing bioreactor design and parameters for different cell types remains a bottleneck. More advanced bioprocessing technologies that can sense and dynamically adjust critical cell culture parameters are required to overcome the unique scale-up barriers faced in cell therapy manufacturing.
  • Storage and supply chain issues for delicate cell products with stability concerns
  • Reimbursement challenges and lack of definitive payment models or market access pathways
  • Variability in international regulatory standards for cell therapy product development

To Know More About This Report, Request a Free Sample Copy

KEY MARKET TRENDS

Global Cell Therapy Bioprocessing Market | Top Market Trends

  • Closed, automated bioprocessing systems are being increasingly adopted in cell therapy manufacturing. These integrated, closed systems allow end-to-end manufacturing within a single device. Automation reduces contamination risks and human errors while improving standardization. Major players offer automated cell processing platforms enabling integrated manufacturing workflows.
  • Advances in cryopreservation technologies are improving cell preservation and managing viability after thawing. New controlled rate freezing devices and optimized cryoprotectants help better regulate ice formation and minimize cell damage during freezing and thawing. This enables extended storage and transportation of cells between sites, overcoming logistical hurdles in cell therapy delivery.

MARKET SEGMENTATION

Market Segmentation – Technology, Indication, Cell Type, and End-User –

Market by Technology: 

  • Bioreactor
    • Bioreactors are an important technology in cell therapy bioprocessing, enabling large-scale cell culture and expansion. As cell therapies move from laboratory to clinical trials and commercialization, there is a high demand for bioreactors that can culture large cell quantities under controlled and validated conditions. 
    • Key vendors offer a range of bioreactor platforms from benchtop to pilot to industrial scale. Features like single-use disposable reactors, microcarrier scaffolds, and perfusion systems allow continuous nutrient feeding and waste removal, supporting rapid cell proliferation.
  • Electrospinning
  • Genome Editing Technology
  • Ultrasonic Lysis
  • Controlflow Centrifugation
  • Cell Immortalization Technology
  • Viral Vector Technology
  • Lyophilization

Market by Indication: 

  • Cardiovascular Disease (CVD)
    • Cardiovascular Disease is projected to be a significant segment under the indication category over the forecast years 2024-2032.
    • Cellular therapies are under exploration as potential interventions for diverse cardiovascular diseases, encompassing conditions like heart failure, stroke, and myocardial infarction. These diseases involve a condition where the permanent loss of cardiomyocytes adversely affects heart function.
    • It facilitates large-scale production of therapeutic cardiac cell products, such as cardiac stem cells, smooth muscle cells, cardiomyocytes, and endothelial cells. These cells hold the potential for regenerating damaged heart tissue, improving blood flow, and restoring contractile function. 
    • Bioprocessing strategies focus on generating clinically relevant cell doses while maintaining purity, potency, and viability. CVD’s presence in the bioprocessing market is driven by the high global prevalence of cardiovascular diseases and the limited availability of effective long-term therapies beyond drug and device interventions.
  • Oncology
  • Wound Healing
  • Orthopedic

Market by Cell Type:

  • Stem Cell
  • Immune Cell
  • Pluripotent Stem Cell
  • Hematopoetic Stem Cell
  • Human Embryonic Stem Cell

Market by End-User:

  • Hospital and Clinic
  • Regenerative Medicine Center
  • Diagnostic Center
  • Academic and Research Institute

GEOGRAPHICAL STUDY

Geographical Study based on Four Major Regions:

  • North America: The United States and Canada
  • Europe: The United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe
  • Asia-Pacific: China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific
    • The Asia-Pacific shows significant potential in the cell therapy bioprocessing space driven by rapid developments in countries such as China, Japan, and South Korea. 
    • Government initiatives and investments aimed at growing domestic cell therapy research and manufacturing capabilities are major factors. Strategic partnerships between companies in APAC and Western biopharma are increasing as well, facilitating knowledge exchange. 
    • For instance, China’s Nanjing Legend Biotech collaborated with Janssen Biotech to develop CAR-T therapy cilta-cel. Contract manufacturing organizations like WuXi AppTec are expanding capacities in the region.
  • Rest of World: Latin America, the Middle East & Africa

MAJOR PLAYERS

Major players in the global cell therapy bioprocessing market: 

  • Dendreon Pharmaceuticals LLC
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Bluebird Bio Inc
  • Novartis International AG
  • Orchard Therapeutics Plc

Key strategies adopted by some of these companies: 

  • In June 2022, Dendreon Pharmaceuticals LLC received FDA approval for a new manufacturing facility in Seal Beach, California to produce immunotherapy Provenge at commercial scale.
  • Amgen Inc, in March 2021, opened a new plant in West Greenwich, Rhode Island dedicated to the manufacturing of new cancer cell therapies including Amgen’s investigational AMG 701 for multiple myeloma.
  • In April 2020, Bristol-Myers Squibb Co acquired a new cell therapy manufacturing facility from Bluebird Bio Inc in Durham, North Carolina to expand its cell therapy production capabilities.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2024-2032
Base Year2023
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments AnalyzedTechnology, Indication, Cell Type, and End-User
Geographies AnalyzedNorth America, Europe, Asia-Pacific, and Rest of World
Companies AnalyzedDendreon Pharmaceuticals LLC, Amgen Inc, Bristol-Myers Squibb Co, Bluebird Bio Inc, Novartis International AG, Orchard Therapeutics Plc, SiBiono GeneTech Co Ltd, Gilead Sciences Inc, Pharmicell Co Ltd, Vericel Corp, Fresenius Kabi AG, Asahi Kasei Corporation, Sartorius AG, Corning Incorporated

TABLE OF CONTENTS

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. MAJOR MARKET FINDINGS
      1. AUTOMATION AND CLOSED PROCESSING SYSTEMS
      2. CRYOPRESERVATION IS ADVANCING WITH CONTROLLED RATE FREEZING DEVICES
      3. THE DEMAND FOR VIRAL VECTOR MANUFACTURING SERVICES IS ESCALATING 
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. INCREASED INVESTMENT AND INNOVATION IN CELL-BASED REGENERATIVE MEDICINE APPROACHES FOR COMPLEX DISEASES
      2. TECHNOLOGY ADVANCEMENTS ENABLING OPTIMIZATION OF CELL HARVESTING, EXPANSION, ENGINEERING, AND DELIVERY STEPS
      3. INDUSTRY AND ACADEMIA PARTNERSHIPS PROVIDING END-TO-END INFRASTRUCTURE AND EXPERTISE
      4. SUPPORTIVE REGULATORY GUIDELINES FOR ACCELERATED APPROVAL PATHWAYS OF CELL THERAPIES
      5. RISING CASES OF CANCER, AUTOIMMUNE DISORDERS, AND DEGENERATIVE CONDITIONS GLOBALLY
    2. KEY RESTRAINTS
      1. HIGH PRODUCTION COSTS AND COMPLEXITY ASSOCIATED WITH CELL THERAPY MANUFACTURE
      2. LIMITATIONS IN SCALING PROCESSES FROM LABORATORY TO CLINICAL SETTING
      3. STORAGE AND SUPPLY CHAIN ISSUES FOR DELICATE CELL PRODUCTS WITH STABILITY CONCERNS
      4. REIMBURSEMENT CHALLENGES AND LACK OF DEFINITIVE PAYMENT MODELS OR MARKET ACCESS PATHWAYS
      5. VARIABILITY IN INTERNATIONAL REGULATORY STANDARDS FOR CELL THERAPY PRODUCT DEVELOPMENT
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
      1. SHIFT TOWARDS CLOSED, AUTOMATED BIOPROCESSING SYSTEMS 
      2. ADVANCES IN CELL PRESERVATION, STORAGE AND THAWING METHODS 
      3. ADOPTION OF SINGLE-USE EQUIPMENT AND DISPOSABLE SYSTEMS FOR FLEXIBLE, MODULAR FACILITIES AND SCALE-UP
      4. INCREASED FOCUS ON ANALYTICS, PROCESS ANALYTICAL TECHNOLOGY (PAT TOOLS), AND AUTOMATION 
    2. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    3. GROWTH PROSPECT MAPPING
      1. GROWTH PROSPECT MAPPING FOR UNITED STATES
      2. GROWTH PROSPECT MAPPING FOR GERMANY
      3. GROWTH PROSPECT MAPPING FOR CHINA
      4. GROWTH PROSPECT MAPPING FOR ISRAEL
    4. MARKET MATURITY ANALYSIS
    5. MARKET CONCENTRATION ANALYSIS
    6. VALUE CHAIN ANALYSIS
      1. RAW MATERIAL SOURCING
      2. MANUFACTURING PROCESSES
      3. DISTRIBUTION AND LOGISTICS
      4.  REGULATORY COMPLIANCE AND QUALITY CONTROL
    7. KEY BUYING CRITERIA
      1. TECHNOLOGY ADAPTABILITY
      2. SUPPLIER RELIABILITY
      3. TRAINING AND SUPPORT SERVICES
      4. INTEGRATION WITH DOWNSTREAM PROCESSES
  5. MARKET BY TECHNOLOGY 
    1. BIOREACTOR
    2. ELECTROSPINNING
    3. GENOME EDITING TECHNOLOGY
    4. ULTRASONIC LYSIS
    5. CONTROL FLOW CENTRIFUGATION
    6. CELL IMMORTALIZATION TECHNOLOGY
    7. VIRAL VECTOR TECHNOLOGY
    8. LYOPHILIZATION
  6. MARKET BY INDICATION
    1. CARDIOVASCULAR DISEASE (CVD)
    2. ONCOLOGY
    3. WOUND HEALING 
    4. ORTHOPEDIC 
  7. MARKET BY CELL TYPE
    1. STEM CELL
    2. IMMUNE CELL 
    3. PLURIPOTENT STEM CELL 
    4. HEMATOPOIETIC STEM CELL 
    5. HUMAN EMBRYONIC STEM CELL 
  8. MARKET BY END-USER
    1. HOSPITAL AND CLINIC 
    2. REGENERATIVE MEDICINE CENTER
    3. DIAGNOSTIC CENTER
    4. ACADEMIC AND RESEARCH INSTITUTE 
  9. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. NORTH AMERICA CELL THERAPY BIOPROCESSING MARKET DRIVERS
      3. NORTH AMERICA CELL THERAPY BIOPROCESSING MARKET CHALLENGES
      4. NORTH AMERICA CELL THERAPY BIOPROCESSING MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN NORTH AMERICA CELL THERAPY BIOPROCESSING MARKET
      6. COUNTRY ANALYSIS
        1. UNITED STATES
          1. UNITED STATES CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        2. CANADA
          1. CANADA CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
    2. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. EUROPE CELL THERAPY BIOPROCESSING MARKET DRIVERS
      3. EUROPE CELL THERAPY BIOPROCESSING MARKET CHALLENGES
      4. EUROPE CELL THERAPY BIOPROCESSING MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN EUROPE CELL THERAPY BIOPROCESSING MARKET
      6. COUNTRY ANALYSIS
        1. UNITED KINGDOM
          1. UNITED KINGDOM CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        2. GERMANY
          1. GERMANY CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        3. FRANCE
          1. FRANCE CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        4. ITALY
          1. ITALY CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        5. SPAIN
          1. SPAIN CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        6. BELGIUM
          1. BELGIUM CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        7. POLAND
          1. POLAND CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        8. REST OF EUROPE
          1. REST OF EUROPE CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
    3. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC CELL THERAPY BIOPROCESSING MARKET DRIVERS
      3. ASIA-PACIFIC CELL THERAPY BIOPROCESSING MARKET CHALLENGES
      4. ASIA-PACIFIC CELL THERAPY BIOPROCESSING MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN ASIA-PACIFIC CELL THERAPY BIOPROCESSING MARKET
      6. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        5. THAILAND
          1. THAILAND CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        6. VIETNAM
          1. VIETNAM CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        7. INDONESIA
          1. INDONESIA CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        8. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        9. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
    4. REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. REST OF WORLD CELL THERAPY BIOPROCESSING MARKET DRIVERS
      3. REST OF WORLD CELL THERAPY BIOPROCESSING MARKET CHALLENGES
      4. REST OF WORLD CELL THERAPY BIOPROCESSING REGULATORY FRAMEWORK
      5. KEY PLAYERS IN REST OF WORLD CELL THERAPY BIOPROCESSING MARKET
      6. REGIONAL ANALYSIS
        1. LATIN AMERICA
          1. LATIN AMERICA CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
        2. MIDDLE EAST & AFRICA
          1. MIDDLE EAST & AFRICA CELL THERAPY BIOPROCESSING MARKET SIZE & OPPORTUNITIES
  10. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
      4. BUSINESS EXPANSIONS & DIVESTITURES
    2. COMPANY PROFILES
      1. DENDREON PHARMACEUTICALS LLC
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      2. AMGEN INC
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      3.  BRISTOL-MYERS SQUIBB CO
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      4. BLUEBIRD BIO INC
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      5.  NOVARTIS INTERNATIONAL AG
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      6.  ORCHARD THERAPEUTICS PLC
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      7.  SIBIONO GENETECH CO LTD
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      8.  GILEAD SCIENCES INC
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      9. PHARMICELL CO LTD
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      10.  VERICEL CORP
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      11.  FRESENIUS KABI AG
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      12. ASAHI KASEI CORPORATION
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      13.  SARTORIUS AG 
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      14. CORNING INCORPORATED
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – CELL THERAPY BIOPROCESSING MARKET 

TABLE 2: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY TECHNOLOGY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 4: GLOBAL BIOREACTOR MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: GLOBAL BIOREACTOR MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 6: GLOBAL ELECTROSPINNING MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: GLOBAL ELECTROSPINNING MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 8: GLOBAL GENOME EDITING TECHNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: GLOBAL GENOME EDITING TECHNOLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 10: GLOBAL ULTRASONIC LYSIS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 11: GLOBAL ULTRASONIC LYSIS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 12: GLOBAL CONTROL FLOW CENTRIFUGATION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 13: GLOBAL CONTROL FLOW CENTRIFUGATION MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 14: GLOBAL CELL IMMORTALIZATION TECHNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 15: GLOBAL CELL IMMORTALIZATION TECHNOLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 16: GLOBAL VIRAL VECTOR TECHNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 17: GLOBAL VIRAL VECTOR TECHNOLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 18: GLOBAL LYOPHILIZATION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 19: GLOBAL LYOPHILIZATION MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 20: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 21: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY INDICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 22: GLOBAL CARDIOVASCULAR DISEASE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 23: GLOBAL CARDIOVASCULAR DISEASE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 24: GLOBAL ONCOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 25: GLOBAL ONCOLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 26: GLOBAL WOUND HEALING MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 27: GLOBAL WOUND HEALING MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 28: GLOBAL ORTHOPEDIC MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 29: GLOBAL ORTHOPEDIC MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 30: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY CELL TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 31: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY CELL TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 32: GLOBAL STEM CELL MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 33: GLOBAL STEM CELL MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 34: GLOBAL IMMUNE CELL MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 35: GLOBAL IMMUNE CELL MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 36: GLOBAL PLURIPOTENT STEM CELL MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 37: GLOBAL PLURIPOTENT STEM CELL MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 38: GLOBAL HEMATOPOIETIC STEM CELL MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 39: GLOBAL HEMATOPOIETIC STEM CELL MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 40: GLOBAL HUMAN EMBRYONIC STEM CELL MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 41: GLOBAL HUMAN EMBRYONIC STEM CELL MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 42: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY END-USER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 43: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY END-USER, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 44: GLOBAL HOSPITAL AND CLINIC MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 45: GLOBAL HOSPITAL AND CLINIC MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 46: GLOBAL REGENERATIVE MEDICINE CENTER MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 47: GLOBAL REGENERATIVE MEDICINE CENTER MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 48: GLOBAL DIAGNOSTIC CENTER MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 49: GLOBAL DIAGNOSTIC CENTER MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 50: GLOBAL ACADEMIC AND RESEARCH INSTITUTE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 51: GLOBAL ACADEMIC AND RESEARCH INSTITUTE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 52: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 53: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY GEOGRAPHY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 54: NORTH AMERICA CELL THERAPY BIOPROCESSING MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 55: NORTH AMERICA CELL THERAPY BIOPROCESSING MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 56: NORTH AMERICA CELL THERAPY BIOPROCESSING MARKET REGULATORY FRAMEWORK

TABLE 57: KEY PLAYERS OPERATING IN NORTH AMERICA CELL THERAPY BIOPROCESSING MARKET

TABLE 58: EUROPE CELL THERAPY BIOPROCESSING MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 59: EUROPE CELL THERAPY BIOPROCESSING MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 60: EUROPE CELL THERAPY BIOPROCESSING MARKET REGULATORY FRAMEWORK

TABLE 61: KEY PLAYERS OPERATING IN EUROPE CELL THERAPY BIOPROCESSING MARKET

TABLE 62: ASIA-PACIFIC CELL THERAPY BIOPROCESSING MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 63: ASIA-PACIFIC CELL THERAPY BIOPROCESSING MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 64: ASIA-PACIFIC CELL THERAPY BIOPROCESSING MARKET REGULATORY FRAMEWORK

TABLE 65: KEY PLAYERS OPERATING IN ASIA-PACIFIC CELL THERAPY BIOPROCESSING MARKET

TABLE 66: REST OF WORLD CELL THERAPY BIOPROCESSING MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 67: REST OF WORLD CELL THERAPY BIOPROCESSING MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 68: REST OF WORLD CELL THERAPY BIOPROCESSING MARKET REGULATORY FRAMEWORK

TABLE 69: KEY PLAYERS OPERATING IN REST OF WORLD CELL THERAPY BIOPROCESSING MARKET

TABLE 70: LIST OF MERGERS & ACQUISITIONS

TABLE 71: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 72: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 73: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR UNITED STATES

FIGURE 4: GROWTH PROSPECT MAPPING FOR GERMANY

FIGURE 5: GROWTH PROSPECT MAPPING FOR CHINA 

FIGURE 6: GROWTH PROSPECT MAPPING FOR ISRAEL

FIGURE 7: MARKET MATURITY ANALYSIS

FIGURE 8: MARKET CONCENTRATION ANALYSIS

FIGURE 9: GLOBAL CELL THERAPY BIOPROCESSING MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2023

FIGURE 10: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY BIOREACTOR, 2024-2032 (IN $ MILLION)

FIGURE 11: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY ELECTROSPINNING, 2024-2032 (IN $ MILLION)

FIGURE 12: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY GENOME EDITING TECHNOLOGY, 2024-2032 (IN $ MILLION)

FIGURE 13: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY ULTRASONIC LYSIS, 2024-2032 (IN $ MILLION)

FIGURE 14: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY CONTROLFLOW CENTRIFUGATION, 2024-2032 (IN $ MILLION)

FIGURE 15: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY CELL IMMORTALIZATION TECHNOLOGY, 2024-2032 (IN $ MILLION)

FIGURE 16: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY VIRAL VECTOR TECHNOLOGY, 2024-2032 (IN $ MILLION)

FIGURE 17: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY LYOPHILIZATION, 2024-2032 (IN $ MILLION)

FIGURE 18: GLOBAL CELL THERAPY BIOPROCESSING MARKET, GROWTH POTENTIAL, BY INDICATION, IN 2023

FIGURE 19: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY CARDIOVASCULAR DISEASE, 2024-2032 (IN $ MILLION)

FIGURE 20: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY ONCOLOGY, 2024-2032 (IN $ MILLION)

FIGURE 21: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY WOUND HEALING, 2024-2032 (IN $ MILLION)

FIGURE 22: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY ORTHOPEDIC, 2024-2032 (IN $ MILLION)

FIGURE 23: GLOBAL CELL THERAPY BIOPROCESSING MARKET, GROWTH POTENTIAL, BY CELL TYPE, IN 2023

FIGURE 24: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY STEM CELL, 2024-2032 (IN $ MILLION)

FIGURE 25: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY IMMUNE CELL, 2024-2032 (IN $ MILLION)

FIGURE 26: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY PLURIPOTENT STEM CELL, 2024-2032 (IN $ MILLION)

FIGURE 27: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY HEMATOPOIETIC STEM CELL, 2024-2032 (IN $ MILLION)

FIGURE 28: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY HUMAN EMBRYONIC STEM CELL, 2024-2032 (IN $ MILLION)

FIGURE 29: GLOBAL CELL THERAPY BIOPROCESSING MARKET, GROWTH POTENTIAL, BY END-USER, IN 2023

FIGURE 30: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY HOSPITAL AND CLINIC, 2024-2032 (IN $ MILLION)

FIGURE 31: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY REGENERATIVE MEDICINE CENTER, 2024-2032 (IN $ MILLION)

FIGURE 32: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY DIAGNOSTIC CENTER, 2024-2032 (IN $ MILLION)

FIGURE 33: GLOBAL CELL THERAPY BIOPROCESSING MARKET, BY ACADEMIC AND RESEARCH INSTITUTE, 2024-2032 (IN $ MILLION)

FIGURE 34: NORTH AMERICA CELL THERAPY BIOPROCESSING MARKET, REGIONAL OUTLOOK, 2023 & 2032 (IN %)

FIGURE 35: UNITED STATES CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 36: CANADA CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 37: EUROPE CELL THERAPY BIOPROCESSING MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 38: UNITED KINGDOM CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 39: GERMANY CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 40: FRANCE CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 41: ITALY CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 42: SPAIN CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 43: BELGIUM CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 44: POLAND CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 45: REST OF EUROPE CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 46: ASIA-PACIFIC CELL THERAPY BIOPROCESSING MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 47: CHINA CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 48: JAPAN CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 49: INDIA CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 50: SOUTH KOREA CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 51: THAILAND CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 52: VIETNAM CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 53: INDONESIA CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 54: AUSTRALIA & NEW ZEALAND CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 55: REST OF ASIA-PACIFIC CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 56: REST OF WORLD CELL THERAPY BIOPROCESSING MARKET, REGIONAL OUTLOOK, 2023 & 2032 (IN %)

FIGURE 57: LATIN AMERICA CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 58: MIDDLE EAST & AFRICA CELL THERAPY BIOPROCESSING MARKET, 2024-2032 (IN $ MILLION)

FAQ’s

FAQs

Cell therapy bioprocessing involves the manufacturing of cell-based therapies, utilizing equipment, technologies, and processes. This contributes to the development of advanced medical treatments for conditions such as cancer, neurological disorders, and cardiovascular diseases.

The cell therapy bioprocessing process includes key steps like cell sourcing, processing, expansion, differentiation, and delivery. Each step is crucial in ensuring the reliable and effective manufacturing of cell therapies.

The market offers bioprocessing instruments, media, reagents, and other tools essential for the consistent and dependable manufacturing of cell therapies. There is a growing focus on optimization and automation for mass production.